William Chu, MD
Interventional Cardiology · Las Vegas, NVNPI 1528018587
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,674 of the $74,532 with a category attached, or 85.4%. 18 manufacturers reported payments, led by Amgen at 46.4% of the total. Reporting peaked in 2020 at $22,359 and has fallen 91.7% since, to $1,859 in 2025. Among interventional cardiology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $290.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$35K
- Chiesi USA, Inc.$19K
- AstraZeneca$14K
- Medtronic$3K
- Abbott$2K
- Abiomed$534
- plus $2K from 12 others
What the payments were for
- Consulting fees$400%
- Speaking & faculty fees$63,67485%
- Travel & lodging$2180%
- Food & beverage$10,47614%
- Education$420%
- Gifts$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 40 | $34,546 |
| Chiesi USA, Inc. | 21 | $19,254 |
| AstraZeneca | 29 | $13,538 |
| Medtronic(2 entities) | 73 | $2,849 |
| Abbott | 21 | $1,759 |
| Abiomed | 14 | $534 |
| Philips North America LLC | 11 | $533 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $235 |
| Heartflow, Inc. | 2 | $214 |
| Cardiovascular Systems Inc. | 6 | $189 |
| Boston Scientific | 4 | $188 |
| Cardiva Medical, Inc. | 16 | $179 |
| Shockwave Medical, Inc | 4 | $170 |
| Itamar Medical Inc | 1 | $130 |
| Bayer | 3 | $68 |
| Novartis | 3 | $65 |
| Johnson & Johnson | 4 | $57 |
| Merck | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$34,123
- KENGREAL$18,759
- FARXIGA$12,916
- Resolute$488
- XIENCE SKYPOINT$389
- COROFLOW$264
- ELCA$255
- CARDIOMEMS$146
- GENERAL - STENTS$133
- WatchPATONE$130
- KENGREAL 50MG/10ML L$125
- CoreValve Evolut$124
- FFRct$122
- Quartet CRT Lead$120
- (6571) Eagle Eye$113
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$112
- Impella$111
- Coronary Orbital Atherectomy System$111
- RESOLUTE ONYX$103
How this compares
$74,532 in reported general payments places this provider in the 90th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $347,370 |
| Repatha SureclickEvolocumab | 155 | $138,942 |
| BrilintaTicagrelor | 135 | $134,549 |
| XareltoRivaroxaban | 58 | $75,332 |
| Repatha SyringeEvolocumab | 13 | $12,681 |
| CorlanorIvabradine Hcl | 14 | $10,923 |
| Atorvastatin Calcium | 240 | $2,037 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 55 | $2,017 |
| Rosuvastatin Calcium | 239 | $2,007 |
| Carvedilol | 181 | $1,651 |
| Metoprolol Tartrate | 262 | $1,615 |
| ClopidogrelClopidogrel Bisulfate | 140 | $1,482 |
| Ranolazine ErRanolazine | 22 | $1,419 |
| Losartan Potassium | 160 | $1,389 |
| Metoprolol Succinate | 91 | $973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $13,538 | $134,549135 claims |
| Johnson & JohnsonXarelto | $57 | $75,33258 claims |
| AmgenCorlanor | $34,546 | $10,92314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Las Vegas
- Cres MirandaLas Vegas$660K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- Neville MistryLas Vegas$36K
- Leon VarjabedianLas Vegas$34K
- Moniz DawoodLas Vegas$29K
- Andrew LuxhojLas Vegas$22K
- Mohi AlkadriLas Vegas$20K
- John BedottoLas Vegas$20K
- James LallyLas Vegas$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.